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Fanconi anemia (FA) is the most common inherited bone marrow failure syndrome. FA patients suﬀer to varying degrees from a
heterogeneous range of developmental defects and, in addition, have an increased likelihood of developing cancer. Almost all FA
patients develop a severe, progressive bone marrow failure syndrome, which impacts upon the production of all hematopoietic
lineages and, hence, is thought to be driven by a defect at the level of the hematopoietic stem cell (HSC). This hypothesis would
also correlate with the very high incidence of MDS and AML that is observed in FA patients. In this paper, we discuss the evidence
that supports the role of dysfunctional HSC biology in driving the etiology of the disease. Furthermore, we consider the diﬀerent
model systems currently available to study the biology of cells defective in the FA signaling pathway and how they are informative
in terms of identifying the physiologic mediators of HSC depletion and dissecting their putative mechanism of action. Finally,
we ask whether the insights gained using such disease models can be translated into potential novel therapeutic strategies for the
treatment of the hematologic disorders in FA patients.
1.Introduction
Fanconi anemia (FA) is a rare, autosomal recessive and X-
linkedhereditarydisorder,whichischaracterizedbyprogres-
sive bone marrow failure (BMF), congenital developmental
defects, and an early onset of cancers such as leukemia
and some solid tumors [1]. In general, the hematologic
manifestations of FA remain the primary cause of morbidity
and mortality, with patients suﬀering from a markedly
increasedriskofmyelodysplasticsyndrome(MDS)andacute
myeloid leukemia (AML). In addition, FA patients are also
predisposed towards various forms of solid tumor such as
squamous cell carcinoma of the head and neck, esophagus,
and gynecologic area [2, 3].
FA is a genetically heterogeneous disorder caused by
inactivating mutations in genes that are thought to function
in an epistatic signaling pathway. Loss of function of any of
the FA family members results in ineﬃcient repair of DNA
damage and deregulation of signaling pathways controlling
cell proliferation and apoptosis. To date, 15 genes associated
with FA in patients have been identiﬁed and cloned: FANCA,
FANCB, FANCC, FANCD1/BRCA2, FANCD2, FANCE,
FANCF, FANCG, FANCI, FANCJ/BACH1/BRIP1, FANL/PH
F9/POG, FANCM, FANCN/PALB2, FANCO/Rad51C [4],
and FANCP/SLX4/BTBD12 (Table 1)[ 5–7]. The FA proteins
appear to function in a common biochemical ubiquitin-
phosphorylation network, the FA signaling pathway, that is
involved in controlling multiple functions related to DNA
repair and the cellular response to stress [8]. Upon DNA
damage, FA proteins are recruited to the site of damage and
assemble to form the FA core complex. This nuclear mul-
tiprotein complex consisting of FANCA, FANCB, FANCC,2 Anemia
Table 1: Members of the FA signaling pathway found in diﬀerent species.
Homo sapiens Mus musculus Danio rerio Drosophila
melanogaster
Caenorhabditis
elegans Archaea Saccharomyces
cerevisiae
FANCA Fanca fanca
FANCB Fancb fancb
FANCC Fancc fancc
FANCD1/BRCA2 Fancd1 fancd1 brca2 brc-2
FANCD2 Fancd2 fancd2 fancd2 fcd-2
FANCE Fance fance
FANCF Fancf fancf
FANCG Fancg fancg
FANCI Fanci fanci fnci-1
FANCJ/BACH1/BRIP1 Fancj fancj dog-1
FANCL/PHF9/POG Fancl fancl fancl
FANCM Fancm fancm fancm fncm-1 hef MPH1
FANCN/PALB2 Palb2 palb2
FANCO/Rad51C Rad51 rad51C
FANCP/SLX4/BTBD12 Slx4 mus312 him-18
References [10][ 11][ 12–14][ 12, 13, 15][ 16][ 16]
FANCE, FANCF, FANCG, FANCL, and FANCM functions as
an E3 ubiquitin ligase and mediates the activation of the ID
complex, which is a heterodimer composed of FANCD2 and
FANCI. Once monoubiquitinated, it interacts with classical
tumor suppressors downstream of the FA pathway including
FANCD1/BRCA2, FANCN/PALB2, FANCJ/BRIP1, and FAN
CO/Rad51C and thereby contributes to DNA repair via
homologous recombination (HR) [9].
Defects in any of the gene products associated with
the FA pathway result in similar cellular abnormalities.
Firstly, cells isolated from FA patients show elevated levels
of chromosomal aberrations and are hypersensitive to DNA
interstrandcrosslinkingagentssuchasmitomycinC(MMC),
cisplatin, diepoxybutane (DEB), and melphalan [17–21].
These DNA alkylating agents covalently link two bases on
opposite strands of the DNA and thereby cause replication
arrestandDNAdouble-strandbreaks,whichultimatelyleads
to cell death. The increased susceptibility of FA cells to these
compounds indicates a defect in the DNA repair machinery
that is usually involved in the resolution of these crosslinks.
T h ee v a l u a t i o no fs u c ha b n o r m a ls t r u c t u r e si nr e s p o n s e
to the clastogenic eﬀect of crosslinking agents provides a
reliable cellular marker for the diagnosis of FA and allows
the identiﬁcation of patients presenting with aplastic anemia
or leukemia that would not be recognized in the absence of
the characteristic physical signs associated with FA. The so-
called chromosome breakage test exposes cultured FA cells
to alkylating agents such as DEB and MMC, in order to
provoke chromosomal abnormalities. While MMC causes
radial chromosomes [18], DEB mainly functions as a bifunc-
tional crosslinking agent inducing chromosomal breakage
or rearrangements [17]. More recently, the FA pathway has
been shown to be involved in the cellular response to DNA
damaging agents that do not cause crosslinks. One example
istheO6-alkylatingagenttemozolomide,whichiscommonly
used in the treatment of glioblastomas. It has been shown
thatinactivationoftheFApathway,inparticularFANCGand
FANCD1/BRCA2,renderscellsmoresusceptibletoapoptosis
following treatment with temozolomide, suggesting that a
functional FA pathway is required for the sensing and/or
resolution of the DNA adducts formed by this agent [19, 20].
An additional cellular phenotype, which can be observed
in response to the treatment of FA cells with DNA damaging
agents like MMC and melphalan, is an exaggerated arrest
of cells in the G2/M phase of the cell cycle. Cultured cells
exhibit a prolonged G2 phase transit and frequently arrest
in G2. This phenotype can be analyzed by ﬂow cytometry
and is useful as an additional diagnostic tool for FA [22–
24]. Recently, this assay has been further modiﬁed to allow
the rapid and accurate determination of complementation
groupsinFApatientsusingretroviral-mediatedgenetransfer
of FA cDNAs to correct the melphalan-induced G2/M arrest
[25, 26].
Finally, cells with a defective FA signaling pathway
demonstrate hypersensitivity to the inhibitory action of
proinﬂammatory cytokines such as tumor necrosis factor α
(TNF-α), interferon-γ (IFN-γ), and macrophage inﬂamma-
tory protein-1-α (MIP-1-α)[ 27, 28]. Both TNF-α and IFN-
γ are produced at abnormally high levels in the serum and
bone marrow (BM) of FA patients and are hypothesized to
play a role in hematopoietic failure [29, 30]. Although the
mechanistic bases for the hypersensitivity of FA cells to IFN-
γ and MIP-1-α remain to be elucidated, it has been shown
that murine BM cells defective in the FA signaling pathway
produce excessive reactive oxygen species (ROS) in response
to treatment with TNF-α [31] .T h e s ee l e v a t e dl e v e l so fR O S
may in turn comprise a source of DNA interstrand crosslinks
andthereforeprovide adirect link between proinﬂammatory
cytokinesandthedefectiveDNAdamageresponseseeninFA
cells.Anemia 3
Although FA cells are well documented to be hyper-
sensitive to both DNA crosslinking agents and to pro-
inﬂammatory cytokines, it has not been formally demon-
strated whether these two phenomena are related to each
other. Perhaps more importantly, the exact identity of the
key players driving BMF in FA patients remains unclear. In
this paper we summarize evidence that the hematopoietic
problems associated with FA are rooted in a stem cell
defect and aim to highlight research that reveals insight into
the mechanisms through which this stem cell depletion is
mediated. We also discuss how this mechanistic data can be
usedasastartingpointtoidentifynewtargetsfortherapeutic
intervention.
2. Hematologic Abnormalitiesin FA
Hematologic abnormalities, which are found in virtually all
FA patients, include cytopenias such as thrombocytopenia
(abnormally low platelet counts in the peripheral blood),
neutropenia (low neutrophil counts), and progressive pan-
cytopenia (abnormality in two or three blood cell lineages)
[3]. At birth, FA patients usually do not show any signs of
these defects and have normal blood cell counts, but, as the
patient grows older, the hematologic complications start to
develop, mainly within the ﬁrst decade of life. Macrocytosis
(enlargement of red blood cells) is usually the ﬁrst to be
detected, followed by thrombocytopenia and aplastic anemia
(insuﬃcient production of red blood cells, leukocytes, and
platelets in the BM), ﬁnally resulting in the characteristic
progressive BMF phenotype [3, 32, 33]. Unless treated, BMF
represents the primary cause of morbidity in FA patients.
In addition to the observed low levels of mature
hematopoietic cells across all lineages, FA patients have also
been found to possess severely compromised hematopoietic
progenitor compartments. Growth of BM hematopoietic
progenitors from FA patients has been shown to be impaired
as they are compromised in their ability to produce colony-
forming unit granulocyte-macrophage (CFU-GM), burst-
formingunit-erythroid(BFU-E),andCFU-granulocyte,ery-
throid,monocyte,megakaryocyte(CFU-GEMM)coloniesin
semisolid culture media in vitro [34, 35]. While hematopoi-
etic progenitors of normal individuals, or even patients with
aplastic anemia, respond to recombinant stem cell factor
(SCF) by improved colony output, FA progenitors largely fail
to respond to stimulation with SCF [34]. In a separate study,
knockdown of FANCC expression in human BM cells using
antisense oligonucleotides resulted in signiﬁcantly reduced
clonal growth of erythroid and myeloid progenitor cells in
vitro[36].Takentogether,thesedataclearlyimplicateadefect
at the level of FA progenitor cells.
As well as suﬀering from the progressive depletion of
normal BM cells, FA patients are also predisposed towards
malignant transformation. Approximately half of all FA
patients present with MDS and/or AML before they are
40 years old [33]. Both of these disorders result from the
dominance of abnormal hematopoietic clones, likely caused
by genetic instability within the hematopoietic stem and/or
progenitor compartments.
3. The Evidence for Hematopoietic Stem Cell
(HSC)Defects inPatients
Since all hematopoietic lineages are compromised in FA
patients, it would seem reasonable to assume that a defective
FA signaling pathway may negatively impact upon the biol-
ogy of HSCs, which comprise the top of the hematopoietic
system hierarchy. However, while it is relatively straightfor-
ward to assess the depletion of mature hematopoietic cells
and myeloid progenitors in FA patients, it is more diﬃcult
to directly examine HSC function. Nonetheless, there are
several lines of evidence in FA patients that suggest that the
HSC pool is compromised.
Firstly, at the immunophenotypic level, FA patients dem-
onstrate signiﬁcantly decreased frequencies of BM CD34+
cells, which are comprised of the HSC and progenitor
compartment. As this is also true for patients that do not
yet show any evidence of BMF, this ﬁnding supports the
hypothesis that FA patients have a defect at the level of the
stem cell [37]. Importantly, this correlates with the ﬁnding
that there are reduced stem/progenitor numbers in umbilical
cord blood taken from newborn FA patients [38]. Thus,
HSC/progenitor depletion appears to precede the decreased
production of mature lineage committed hematopoietic cells
and may have already begun during early development.
Secondly, the BMF syndrome can be corrected by
allogeneic HSC transplantation using minimal conditioning
[39, 40]. Thus, in a mixed chimera setting, normal donor
HSCs are able to permanently reconstitute the failing
hematopoietic system to a corrective level, regardless of the
environmentofpatientFAhematopoieticandnichecellsthat
the donor cells are infused into. As well as eliminating the
possibility that the FA HSC niche has a dominant role to
play in progressive BMF, this also suggests that FA HSCs are
defective relative to their normal counterparts.
Finally, the phenomenon of reverse mosaicism reveals
that the FA defect can be corrected with a single functionally
normal HSC. Reverse mosaicism occurs as a consequence
of the correction of one of the patient’s nonfunctional
FA alleles within a somatic cell clone. In FA patients,
this correction has been documented to arise from either
the genetic recombination of two compound heterozygote
mutations in a FA gene, resulting in the production of a
single functional allele; or from spontaneous point/frame
shift mutations that restore function to the inactivated gene
[41–43]. Importantly, the corrected clone must demonstrate
a survival advantage over its noncorrected counterparts in
o r d e rt ob ea b l et oe x p a n dt os u ﬃcient numbers to facilitate
detection and confer a therapeutic eﬀect. This survival
advantage must be present in FA patients, as in several
independent instances, a single corrected hematopoietic
clone has been shown to support the hematopoietic function
and survival of the patient, despite the fact that cells
within other somatic tissues did not contain the correcting
mutations [41, 42]. Although these spontaneously reverting
clones have been documented to persist for a number
of years in several patients, it is still possible that the
correcting mutation occurred in a long-lived progenitor4 Anemia
cell as opposed to an HSC. However, one intriguing study
has described the occurrence of reverse mosaicism from a
single clone in monozygotic FA twins. Although the twins
presented with nonhematologic symptoms of FA and their
skin ﬁbroblasts were sensitive to DNA crosslinking agents,
theirhematopoieticcellsappearedtofunctionnormally[43].
Upon molecular analysis, it was revealed that the twins both
possessed a revertant clone with exactly the same correcting
mutation. Presumably, a single somatic hematopoietic cell
must have been subject to this correcting point mutation in
utero, and then its descendants must have been distributed
between both twins during gestation. Since this single clone
was able to reconstitute the hematopoietic system of both
twins for more than two decades, the original mutation
must have occurred within an HSC. This observation clearly
demonstrates the selective advantage of corrected FA HSCs
over noncorrected HSCs and therefore reveals a survival
defect at the level of HSCs in FA patients.
4.Model Systemsto Study FAHSCs
Clinical observations from FA patients provide some evi-
dence that allows us to implicate a defect at the level of
HSCs in driving the BMF disease phenotype. Nonetheless,
experimental model systems must be employed to directly
interrogatethefunctionofHSCsdefectiveintheFAsignaling
pathway in a reproducible manner. The “gold standard” for
assessing the capacity of HSCs to be able to diﬀerentiate to
form all mature lineages of the hematopoietic system, while
also being capable of self-renewal, is to perform BM trans-
plantation and measure long-term multilineage engraftment
within the recipient. Ideally, this assay would be performed
with a limiting dilution of HSCs and involve at least one
serial transplantation into a secondary recipient. While this
rigorous assessment clearly cannot be performed in patients,
a number of surrogate assays have been developed in order
to dissect human HSC biology.
As brieﬂy discussed above, it is possible to measure the
frequency of a range of human hematopoietic progenitor
compartments by their ability to form colonies in semisolid
media supplemented with various hematopoietic growth
factors. However, in the case of FA, while a defective HSC
poolmaycauseadecreasedfrequencyofprogenitorcells,this
assay does not allow the direct evaluation of whether this is
the case, as it only enumerates the downstream progeny of
HSCs. One technique that has been developed to measure
the frequency of more primitive cells based on their ability to
maintaintheoutputofhematopoieticprogenitorcellsduring
extended periods of in vitro culture is the long-term BM
culture assay, also known as Dexter culture [44–46]. This
approach has been applied to the study of patient-derived FA
HSCs with varying results. While Butturini and Gale were
able to demonstrate that FA BM cells were able to generate
long-term cultures that were able to initiate secondary long-
term cultures with robust output of diﬀerentiated myeloid
cells, Martinez-Jaramillo et al. found that long-term cultures
seeded with FA patient marrow were drastically curtailed in
terms of output of myeloid and erythroid progenitor cells
[47, 48]. These diﬀerences likely reﬂect either disparities
in the culture conditions employed, which FA HSCs may
be particularly sensitive to, or to interpatient variation, for
example due to diﬀerences in the degree of BMF at the time
of BM biopsy. Nonetheless, these two studies clearly serve as
a proof of principle for the use of this approach in assessing
FA HSC function and may be useful in the evaluation of
potential novel therapeutic strategies using primary patient
material.
While the long-term BM culture approach can be
successfully employed as a surrogate assay for HSC function,
it does suﬀer from some critical drawbacks. Hence, to date,
it has proven extremely diﬃcult to engineer an in vitro
system that encompasses the extrinsic cues that maintain
HSCs within their in vivo niche. One possible solution to
this problem is the murine xenotransplantation system. This
approach takes advantage of the fact that HSCs derived
from human umbilical cord blood, BM, and mobilized
peripheral blood can be successfully engrafted into immune-
deﬁcient mice [50–53]. To date, there have been no reports
of successful direct transplantation of FA patient HSCs
using the immune-deﬁcient mouse models that are currently
available. However, Cohen-Haguenauer and colleagues were
able to demonstrate long-term engraftment of retroviral
gene corrected CD34+ cells from an FA patient in com-
plementation group A, using the nonobese diabetic/severe-
combine immunodeﬁciency (NOD/scid) immune-deﬁcient
mouse model as a recipient [54]. Moreover, a second
group took advantage of the “humanized” NOD/scid IL-
2Rγ−/−/SGM3 (NSG/SGM3) mouse model, which com-
bines a profoundly immune-compromised background with
transgenic expression of the recombinant human growth
factors SCF; granulocyte macrophage colony-stimulating
factor (GM-CSF); interleukin-3 (IL-3), in order to facilitate
robust engraftment of FA patient AML cells [55]. Taken
together, these studies suggest that it may be possible to
develop a human FA HSC xenotransplant system given an
appropriate murine recipient model and an adequate supply
of patient CD34+ cells. Unfortunately, given the fact that FA
patientstendtoalreadybesuﬀeringfrommarrowhypoplasia
upondiagnosis,itisunlikelythatthisapproachwillbewidely
accessible to the research community.
A potential novel source of FA HSCs for use in the
laboratory is through the directed diﬀerentiation of patient-
speciﬁc induced pluripotent stem (iPS) cells. A recent study
by Tulpule et al. showed that in vitro diﬀerentiation of FA-
deﬁcientpluripotent celllines,inthiscasehumanembryonic
stem(ES)cellsknockeddownforeitherFANCAorFANCD2,
canbeusedtoshowadevelopmentaldefectinhematopoietic
speciﬁcation, thereby highlighting pluripotent cell lines as
av a l u a b l et o o lt os t u d yF A[ 56]. However, there are two
major barriers to the application of iPS cell technology
in the study of FA HSCs. Firstly, there are currently no
robust protocols available for the directed diﬀerentiation of
bona ﬁde HSCs from either human ES or human iPS cells
[57]. The second barrier is it appears that the absence of a
functional FA signaling pathway restricts the attainment of
pluripotency when somatic tissues are reprogrammed using
the approach devised by Takahashi and colleagues, namely,Anemia 5
via the retroviral delivery of exogenous OCT4, SOX2, KLF4,
and c-MYC [58, 59]. However, recent work from M¨ uller
and colleagues would seem to suggest that somatic cells
from FA patients can be successfully reprogrammed to a
state of pluripotency, albeit at lower eﬃciencies than normal
counterparts, by incorporating slight modiﬁcations to the
reprogramming procedure, such as reducing oxygen tension
[60].
Recently, an alternative cellular reprogramming ap-
proach was established for the generation of transplantable
HSC/progenitors from normal adult somatic tissues. It was
demonstrated that it is possible to convert human ﬁbroblasts
directlytomultipotenthematopoieticprogenitorsviaOCT4-
dependent cellular programming without transiting through
a pluripotent state [61]. Notably, using this approach,
the authors could demonstrate multilineage engraftment
potential using the murine xenotransplant model. It would
be intriguing to establish whether this approach could be
used to directly bypass the reprogramming deﬁciency that
FA patient ﬁbroblasts suﬀer from when they are subject to
the iPS cell-derivation methodology.
5.AlternateModelSystemsforFA
Studying the etiology of human disease ideally involves the
use of human model systems. However, given the previously
discussed constraints that are associated with studying HSC
biology in FA, namely, the lack of an abundant source of
patient HSCs to act as a starting material and the absence
of a transplantation system to assess HSC function, it has
been necessary to develop animal model systems for this
disease. Fortunately, the FA signaling pathway has been
well conserved throughout evolution; thus, there are several
potential model systems available (Table 1).
Five of the 15 human genes can be found in plants,
including components of the core complex (FANCM and
FANCL), the FANCD2 component of the ID complex, as
well as the downstream eﬀectors FANCD1 and FANCJ
[62]. Orthologs for FANCM can also be found in Saccha-
romyces cerevisiae (MPH1) and Archaea (Hef), while six
of the FA proteins have clear orthologs in Caenorhabdi-
tis elegans: BRC-2 (FANCD1/BRCA2), FCD-2 (FANCD2),
FNCI-1 (FANCI), DOG-1 (FANCJ), FNCM-1 (FANCM),
and HIM-18 (FANCP/SLX4/BTBD12) [12, 13, 16]. In the
genome of Drosophila melanogaster, six orthologs of the FA
complementation groups are encoded: Brca2, Fancd2, Fancl,
Fancm, Rad51C and Mus312 (FANCP/SLX4/BTBD12) [12–
14]. Meanwhile, in vertebrates, the chicken DT40 B cell line
has been extensively used to study the eﬀects of loss of
function in the FA signaling pathway, including inactivation
of FANCG, FANCD2, FANCC, FANCI, and FANCP [63–68].
Notably, the complete FA gene family can only be found
in vertebrates; thus, the DT40 cell line gives a good system
to study molecular interactions of the whole FA pathway
[69]. Although these model systems are suitable for pathway
analysis, a hematopoietic transplantation system is required
for the study of HSC biology.
6. Transplantation Models for HSC
Research in FA
There are a number of vertebrate model systems that have
been used to interrogate HSC biology. In the zebraﬁsh,
transplantation of whole kidney marrow cells into lethally
irradiated recipient ﬁsh was shown to be radioprotective,
speciﬁcally rescuing the ablation of the hematopoietic sys-
tem that is observed in nontransplanted ﬁsh [70]. This
demonstrated that transplantable zebraﬁsh HSCs were to be
found in the adult kidney. The recently identiﬁed existence
of histocompatibility genes in the zebraﬁsh has allowed
the further improvement of this transplant system [71].
Although zebraﬁsh contain the full complement of FA family
members found in humans, loss of function models have
only been described for a few complementation groups
[11]. The knockdown of the zebraﬁsh ortholog of FANCD2
using an antisense morpholino approach leads to similar
developmentaldefectsasthoseobservedinsomeFApatients,
including decreased body size, microcephaly, and microph-
thalmia [72]. This suggests that the FA pathway plays a
similar role in zebraﬁsh and humans. While the morpholino
approachisparticularlyusefulforthestudyofageneproduct
during development in the zebraﬁsh, it is not appropriate
for the ongoing evaluation of gene function in the adult
organism. To date, zebraﬁsh mutant lines for FANCL and
FANCD1 have been described [73]. Although these ﬁsh
have an interesting defect in sex determination, they have
no documented defects in hematopoiesis. Nonetheless, it is
possible that a more detailed assessment of the HSC function
ofthesemutantﬁshusingthetransplantationassaydescribed
above may yield a phenotype.
The mouse is by far the most frequently used model
system employed to study mammalian hematology. The
transplant system for mice is well established, and the
immunophenotypic identiﬁcation of murine HSCs and their
committed progeny has dramatically improved over the last
decade such that HSCs can be prospectively puriﬁed to
a frequency of around 1 in 4 cells using ﬂow cytometry
[74, 75]. A number of murine models for FA have been
developed. Knockout models exist for components of the
FA core complex (FANCA, FANCC, FANCG, FANCF, and
FANCM), FANCD2, and the downstream eﬀectors FANCD1
and FANCP [5, 76–78]. As in FA patients, a number of
common cellular phenotypes are present across the diﬀerent
mouse models. These include defective regulation of the
cell cycle and apoptosis; spontaneous genomic instability
including chromosome breakage and radial chromosomes;
increased sensitivity towards DNA interstrand crosslinking
agents such as DEB, MMC, and cisplatin [79]. Our discus-
sion will focus on the hematologic defects in these mice, but
a detailed overview of the nonhematopoietic phenotypes can
be found in [80].
Of the models for FA core complex loss of function, the
phenotypes of FA core complex Fanca−/−, Fancc−/−,a n d
Fancg−/− mice are almost identical [78]. Their splenocytes
and BM progenitors show MMC hypersensitivity. In addi-
tion, the BM progenitors are also hypersensitive towards
IFN-γ and TNF-α in vitro and in vivo [28, 49, 81–85]. The6 Anemia
peripheral blood is normal in Fancc−/− and Fancg−/− mice;
however, Fanca−/− mice show mild thrombocytopenia in
young (8–10 weeks), but not in older mice [86]. Regard-
ing the BM, Fancg−/− mice demonstrate a defect in the
proliferation of mesenchymal stem/progenitor cells and a
compromised ability to promote HSC engraftment in vitro
or in vivo [87]. Although Fanca−/− and Fancc−/− mice do
notdemonstratereducednumbersofHSCsasdeterminedby
ﬂow cytometry analysis, they do have impaired proliferation
of progenitors in vitro and show a decreased long-term
repopulating ability of HSCs in competitive transplantation
assays in vivo (Figure 1), which may be related to the
development of BMF in FA patients [88–90]. Relating to
this, ex vivo expanded Fancc−/− HSCs demonstrate a dra-
matically reduced repopulation ability indicating impaired
HSC maintenance during stress [91, 92]. Notably, the HSC
phenotype of Fanca−/− and Fancc−/− mice can be corrected
via retroviral-mediated delivery of the corresponding FA
cDNA, formally demonstrating that the defect in the FA
signaling pathway is responsible for this phenotype [93–95].
Of the two other murine models which are knocked out
for components of the core complex, neither the Fancf −/−
nor the Fancm−/− mice have been shown to have any
hematologic defects to date, although extensive analysis of
the HSC compartment using transplantation assays may not
have been performed [76, 77].
Two independent murine Fancd2−/− models have been
developed [96, 97]. Fancd2−/− mice have a reduced HSC
content, leading to signiﬁcantly reduced frequencies of late-
developing cobblestone area forming cells in vitro and defec-
tiveshort-andlong-termrepopulatingabilityinvivo[96].Of
potential importance is the fact that both Fancd2−/− models
demonstrate a reduction in the frequency of quiescent HSCs,
which may relate to their reduced engraftment capacity.
Interestingly, treatment with the antioxidant resveratrol
is able to partially correct the hematopoietic defects in
Fancd2−/− mice [97].
The mice that harbor a hypomorphic mutation in
the FA downstream eﬀector Fancd1 (Fancd1/Brca2Δ27/Δ27)
have a more severe hematopoietic phenotype than the FA
core complex knockout mice [80] .T h ep e r i p h e r a lb l o o di s
normal, but the function of the more immature hematopoi-
etic compartment is signiﬁcantly compromised, including
decreased proliferative capacity of the progenitor compart-
ment and a profoundly reduced competitive repopulation
capacity of HSCs [98]. Notably, wild-type or gene-corrected
Fancd1Δ27/Δ27 HSCs transplanted into Fancd1Δ27/Δ27 mice
demonstrated a selection advantage, which would appear to
recapitulate the phenomenon of reverse mosaicism that has
been observed in some FA patients [98, 99].
Despite the fact that a number of the FA murine models
described above do demonstrate a defect in HSC function
during BM transplantation, none of the mice suﬀer from
the progressive BMF that is almost universally prevalent in
FA patients. As described below, it is possible to provoke
a BMF-like phenotype in some of these murine models by
the application of stress situations other than BM trans-
plantation, such as in vivo exposure to crosslinking agents
or oxidative stress [86, 100]. However, the only single gene
deleted FAmousemodel thatappearstodemonstrateaspects
of spontaneous BMF is the recently described Btbd12
−/−
(Fancp−/−) mouse [5]. Btbd12 is the mouse ortholog of
the evolutionarily conserved SLX4 protein, which is a key
regulatorofnucleasesandcriticalforDNAdamageresponse.
These mice are born at sub-Mendelian ratios; have reduced
fertility; are growth retarded and suﬀer from developmental
defects including microphthalmia. In addition, cells from
Btbd12
−/− animals spontaneously accumulate chromosomal
damage and are particularly sensitive to DNA crosslinking
agents. However, of particular import is the observation that
Btbd12
−/− mice are prone to peripheral blood cytopenias
and have decreased myeloid and pre-B-cell progenitor
content in the BM. The HSC phenotype of these mice has
not been reported to date, but it would be particularly
informative to assess how this relates to the other murine
FA models and whether there is a progressive, spontaneous
loss of the HSC pool as these mice age. The fact that
Btbd12
−/− mice more closely mimic the phenotype of FA
patients begs the question as to why this is not the case
for other murine models of FA. One possibility is that the
FA proteins targeted in the other FA mice do not have an
equivalent role in humans and mice. While this is certainly
possible, the cellular phenotype relating to their DNA
damage response; cell cycle defects; proapoptotic phenotype;
hypersensitivity to proinﬂammatory cytokines appears to be
conserved across the species barrier. A second possibility
is that most of the FA murine models developed to date
are in fact hypomorphic. Again, this would not seem to
correlate with the abnormal cellular phenotypes that are
obtained in these models. A third possibility is that the mice
are not exposed to an environmental stimulus that drives
BMF. While this possibility will be discussed at some length
below, it would not explain the fact that BMF is observed
in the Btbd12
−/− model, which is presumably exposed to
a similar environment as all the other FA mice models.
Another alternate explanation is that BTBD12 has additional
functions outside the FA pathway. As a putative scaﬀolding
protein for DNA nucleases, it could certainly be involved in
other forms of DNA repair. Conversely, it is apparent that the
phenotypes of the FA murine models become more severe
thefurtherdownstreamwithinthepathwaythetargetedgene
is proposed to act. While this may again relate to the other
knockout models actually being hypomorphic in terms of FA
pathway signaling, it is also possible that the downstream
proteins, which are directly involved in DNA repair, can
retain some function in the complete absence of upstream
signaling. In this context, it would be interesting to examine
BTBD12 activity in the other existing murine FA models.
While the Btbd12
−/−/Fancp
−/− mouse is the only single
FA gene loss of function model to recapitulate some aspects
of the BMF seen in patients, the compound loss of function
of Fancc−/− and Fancg−/− also results in spontaneous hema-
tologicdefectsincludingBMF,AML,MDS,andcomplexran-
dom chromosomal abnormalities [101]. This would again
seem at odds with the idea that the FA signaling pathway
is epistatic and suggests that some of the FA proteins have
divergent functions. However, an alternative interpretation
would be that the single Fancc−/− and Fancg−/− mutationsAnemia 7
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Figure 1: Murine models of FA do not have reduced numbers of immunophenotypically deﬁned HSCs but do have lower frequencies of
functionally deﬁned HSCs. (a) Representative FACS plots showing the gating scheme which is employed to enumerate long-term HSCs
(LT-HSC) in the BM which are deﬁned by the following combination of immunophenotypic markers: Lineage-, c-Kit+, Sca-1+, Flk2−,
and CD34−. For illustrative purposes, the compartments enriched for short-term HSC (ST-HSC) and multipotent progenitors (MPP) are
also shown. (b) Based on the FACS methodology shown in (a), the frequency of LT-HSCs does not diﬀer signiﬁcantly in wild-type (WT)
mice compared to FA mice. The mean frequency of immunophenotypically deﬁned LT-HSC found in the BM of WT (n = 21), Fanca−/−
(n = 12), Fancc−/− (n = 6), and Fancg−/− (n = 6) mice is shown, ± SEM. NS = P>0.05 by comparison using ANOVA. (c) Schematic
representation of the competitive repopulation assay employed to assess the relative frequency of HSCs in WT versus either Fanca−/− or
Fancc−/− mice. BM from FA (3 × 106 t o t a lB Mc e l l s )a n dW T( 2× 106 total BM cells) mice were coinjected into lethally irradiated (10Gy
total body irradiation) recipient mice at a 3:2 ratio, respectively. At four months posttransplant, peripheral blood was harvested from
recipient mice and the percentage contribution of FA cells to the peripheral blood was determined by FACS analysis, taking advantage of the
diﬀerential expression of CD45 subtypes on the surface of FA (CD45.1+ and CD45.2−) and WT (CD45.1+ and CD45.2+) leukocytes. If FA
BM contained the same number of functionally deﬁned HSCs as WT BM, then the FA HSCs would be predicted to contribute to 60% of the
peripheral blood chimerism at 4 months posttransplant. (d) FA HSCs have a severe engraftment defect compared to WT HSCs. The mean
relative frequency that FA or WT cells contributed to peripheral blood leukocyte engraftment at 4 months post-transplantation is shown
± SEM. ∗∗ = P<0.001 for comparison of WT versus FA chimerism using ANOVA. n = 21 for WT versus Fanca−/−, and for WT versus
Fancc−/−. Fancc−/−, Fancg−/− and Fanca−/− mice have all been previously described [49].8 Anemia
are in fact hypomorphic for HSC function. Clearly this is a
very interesting model system that may be used to gain some
insight into the role of abnormal HSC biology in BMF.
While the murine models of FA seem to be the best
systemcurrentlyavailableforinterrogatingtheHSCdefectin
thisdisease,itispossiblethattheywillneverfullyrecapitulate
the hematologic disorders observed in patients. Therefore, it
may be beneﬁcial for those in the FA research community
to develop a large animal model of FA. While such an
undertakingwouldrequireasigniﬁcantﬁnancialinvestment,
large animal transplant models such as the existing canine
and primate systems have already given us unique insights
intohumanHSCbiologyandhavebeeninvaluableinhelping
to develop novel therapeutic modalities for other diseases
[102].
7. CellularDNA CrosslinkingAgents and
HSC Depletion in FA
The observation that none of the currently available models
of FA fully phenocopies the progressive BMF observed in
patients may relate to the lack of an environmental and/or
endogenous factor that drives HSC loss. Since FA cells are
invariably hypersensitive to DNA crosslinking agents, result-
ing in cell cycle arrest and apoptosis, it is not unreasonable to
focus upon the identiﬁcation of potential crosslinking agents
in FA patients in the search for a physiologic mediator of
HSC depletion (reviewed in [103]).
Cellular ROSs are one of the chemical entities that are
frequently proposed to act as a source of DNA damage in
FA cells. Fuelling this speculation is the observation that
primary FA cells from patients and murine models of the
disease are more susceptible to karyotypic abnormalities
induced by oxygen; have a proapoptotic response following
exposure to elevated oxygen and/or ROS; are propagated
much more eﬀectively under low oxygen tensions [54, 104–
108]. Conﬁrmatory evidence is provided by a study in
which compound inactivating mutations of FANCC and
the ROS detoxifying enzyme Cu/Zn superoxide dismutase
(SOD) in mice led to BM hypocellularity [86]. Relating to
this, a recent study by Li and colleagues demonstrated a
direct functional interaction between FANCD2 and FOXO3a
in human lymphoblast cell lines following challenge with
H2O2 [109]. This interaction was speciﬁc for treatment
with ROS-inducing agents and was absent in cell lines
where the FA pathway was nonfunctional. Using a retroviral
overexpression strategy, it was also possible to demonstrate
that the FANCD2-FOXO3a interaction was involved in
protecting cells from oxidative stress via enhancing the
induction of antioxidant genes that are direct targets of
FOXO3a. Intriguingly, several groups have also shown that
the balance of normal HSC homeostasis, including their
genetic integrity, is dependent upon ROS levels, suggesting
that the ROS-sensitive phenotype of FA cells may represent
an exaggerated form of normal HSC behavior [110–115].
Reactive aldehydes comprise another potential source of
cellular DNA crosslinking agent that may deplete FA HSCs
in vivo.F Ad e ﬁ c i e n tc e l ll i n e sa r eh y p e r s e n s i t i v et ob o t h
acetylaldehyde and formaldehyde in vitro, while exposure
of FA proﬁcient cells to acetylaldehyde in vitro results in
activation of the FA signaling pathway [116]. Moreover, it
has recently been shown that in mice which have compound
inactivating mutations of FANCD2 and the acetylaldehyde
detoxifying enzyme ALDH2, postnatal exposure to ethanol,
the metabolic precursor for acetylaldehyde, results in BMF
[117]. These Fancd2−/−Aldh2−/− mice are also predisposed
to spontaneously develop acute leukemia, hence further
phenocopying the disease progression in patients.
8. ReplicativeStress andDNA Damage inHSCs
Since DNA synthesis can be considered a form of DNA
damage, replicative stress may also be a candidate for
HSC depletion in FA. Indeed, in FA competent cell lines,
upon induction of replicative stress, FANCD2, FANCM,
and the Blooms complex are localized to discrete fragile
sites on sister chromatids during mitosis [118, 119]. These
fragile sites comprise common chromosomal break points
and are also the location at which stress-induced ultraﬁne
DNA bridges form. In human and murine FA-deﬁcient
cells, including FA HSC/progenitors, there is an increased
number of ultraﬁne DNA bridges compared to their wild-
type counterparts [120]. This correlates with an increased
frequency of cytokinesis failure, as assessed by the number
of binucleated HSC/progenitors, and an increased rate of
apoptosis. Thus, it is hypothesized that the FA pathway is
involved in the resolution of these spontaneously occurring
ultraﬁne bridges and that the absence of a functional FA
pathwayleadstocytokinesisfailurefollowedbyprogrammed
cell death, or to genetic instability. Such a mechanism would
be an attractive explanation for the progressive BMF seen in
FA patients, as HSCs would potentially be depleted as they
were induced into cycle.
9. Proinﬂammatory CytokinesasPotential
Mediatorsof HSCDepletion
In addition to an inability to resolve some forms of DNA
damage, FA cells are also hypersensitive to the inhibitory
action of certain proinﬂammatory cytokines. Proinﬂamma-
tory cytokines are potential physiologic mediators of BMF
in FA, since HSCs are routinely exposed to a range of
proinﬂammatory cytokines during either infection or as part
of the etiology of diseases with an inﬂammatory component,
such as rheumatoid arthritis.
The investigation into the role of proinﬂammatory
cytokinesinthehematologicdefectsfoundinFApatientswas
driven by the observation that such signaling molecules are
expressed at elevated levels in some FA patients due to aber-
rant activation of intracellular stress-response signaling [29,
30, 121–124]. Although this abnormal expression pattern
could conceivably be a cause or an eﬀect of progressive BMF,
subsequentworkestablishedthatFA-deﬁcienthematopoietic
progenitor cells were subject to an inhibition of proliferation
and increased apoptosis following treatment with TNF-α,
IFN-γ,a n dM I P - 1 - α [27, 29, 125–127]. Although there is no
mechanistic data to explain the sensitivity of FA cells to MIP-
1-α, some signaling pathway analysis has been performed toAnemia 9
dissect how the inhibitory eﬀect of IFN-γ and TNF-α on FA
deﬁcient cells is mediated.
In FANCC deﬁcient cells, IFN-γ exposure results in
decreased phosphorylation of STAT1, 3, and 5 and, in the
case of STAT1, is the result of FANCC binding to STAT1
and being required for its docking with the IFN-γ receptor
[128, 129]. Although JAK/STAT signaling is involved in
cell survival, the suppression of STAT1 signaling alone in
FANCC-deﬁcient cells may not explain IFN-γ inhibitory
eﬀects since hematopoietic progenitors from Stat1−/− mice
are resistant to IFN-γ treatment [129]. In addition, double-
stranded RNA-dependent protein kinase (PKR) is consti-
tutively activated in FANCC−/− cells and demonstrates an
increased binding aﬃnity for double-stranded RNA [127].
While overexpression of PKR leads to an increased apoptotic
response of FANCC−/− cells to IFN-γ, inhibition of PKR
signaling partially rescues the hypersensitivity phenotype,
thus establishing a role for PKR downstream of IFN-γ.I na
separate study, overexpression of a dominant negative form
of the PKR activator RAX resulted in increased resistance
of Fancc−/− murine embryonic ﬁbroblasts to IFN-γ [130].
Although the FANCC protein does not directly bind to
PKR,itmaypromoteresistancetoIFN-γ-mediatedapoptosis
via its interaction with Hsp70 [127]. Intriguingly, Pang
and colleagues were able to generate mutant versions of
the FANCC protein that were able to correct the crosslink
repair defect of FANCC-deﬁcient cells and rescued FANCD2
monoubiquitination yet were unable to facilitate a normal
activation of STAT1 and resulted in continued hypersensitiv-
ity of the cells to IFN-γ and TNF-α [131]. This uncoupling
of the characteristic DNA repair defect of FA cells and
their hypersensitivity to treatment with proinﬂammatory
cytokines suggests that some members of the FA pathway
may hold multifunctional roles outside of the canonical
function in the sensing and repair of DNA interstrand
crosslinks. Whatever its mechanism of action, it would
seem that IFN-γ can elicit its eﬀect at the level of FA
HSCs as well as in progenitors, since pretreatment of either
Fancc−/−, Fanca−/−,o rFancg−/− mice with IFN-γ facilitates
the depletion of endogenous HSCs to such an extent that
wild-type HSCs can be successfully engrafted into these mice
without additional myeloablative conditioning [132, 133].
In the case of TNF-α-mediated suppression of FA
hematopoietic cells, there is some evidence to implicate a
link between DNA damage and TNF-α signaling. Treatment
of Fancc−/− mice with either LPS or TNF-α results in
an exaggerated production of intracellular ROS within
HSC/progenitors that may be linked to the requirement
for FANCD2 monoubiquitination in the FOXO3a-mediated
suppression of oxidative stress [31, 109, 134, 135]. Elevated
ROS expression in response to TNF-α treatment correlates
with increased DNA damage and HSC/progenitor senes-
cence, which can be rescued by the addition of the ROS
scavenger molecule N-acetylcysteine (NAC) or by inhibition
of the TNF-α signaling axis. Interestingly, ex vivo treatment
of Fancc−/− HSC/progenitors with TNF-α results in a ROS-
dependent increase in genetic instability; development of
TNF-α resistant clones; an increased predisposition towards
AML upon transplantation of treated cells into recipient
mice [31]. Relating to this, extended ex vivo culture of
Fancc−/− cells leads to an exaggerated reduction in HSC
content via induction of apoptosis in addition to an
increased frequency of cytogenetic abnormalities and risk of
malignant transformation which appears to be related to an
acquired resistance to TNF-α [92]. Inappropriate activation
of the apoptosis signal-regulating kinase-1/p38 MAP kinase
signaling pathway has been identiﬁed as mediating the
proapoptotic response of Fancc−/− cells to TNF-α, although
it is not clear whether this is downstream of the induction
of DNA damage [134, 136]. TNF-α would also appear to
exert its eﬀect upon FA HSCs, since inhibition of TNF-
α signaling in Fancc−/− HSCs via ectopic expression of
the homeobox transcription factor HOXB4 partially rescues
their engraftment defect [137]. Of particular note, TNF-α
would also appear to act as a negative regulator of wild-
type HSC function in mice, again suggesting that FA HSCs
act as a hypersensitive version of normal HSCs [138]. Taken
together, it would appear that TNF-α is able to mediate DNA
damage, HSC depletion, and hematologic transformation in
the setting of FA-deﬁcient HSC/progenitors.
It is important to note that the majority of the exper-
iments linking proinﬂammatory cytokines to a role in FA
HSCdepletionhavebeenperformedusingonlythe Fancc−/−
murine model. However, the previously discussed studies,
which demonstrate an inhibitory role of either TNF-α or
IFN-γ in FA patient-derived cells or in murine models of
alternate complementation groups, would seem to suggest
that this hypersensitivity may be a generic feature of FA cells
[29, 133].
10. CurrentTherapeutic Modalities for FA
Hematopoietic stem cell transplantation (HSCT) derived
from the BM, mobilized peripheral blood, or umbilical
cord blood of a human-leukocyte-antigen-(HLA-) matched
donor currently remains the only curative treatment option
for the hematologic abnormalities in FA [139]. In fact,
FA was the ﬁrst disease that was successfully treated by
transplantation using cord blood from an unaﬀected HLA-
identical sibling as a starting material [140]. Signiﬁcant
barriers to successful transplantation of FA patients include
thechallengeofcreatingasatisfactorypreparativeregimenin
light of the patient’s acute sensitivity to chemotherapeutics
and radiotherapy [39, 141, 142]; the availability of an HLA-
matched donor who does not suﬀer from the disease. Most
patients are dependent on alternative donor grafts from an
HLA-unmatched donor as only a very small number of
patients have an unaﬀected, matched sibling donor (less
than 25%). However, advances in the conditions used in
preparativeregimensallowtheachievementofalmostsimilar
transplant outcomes for both cases, with survival rates
of 52–88% for mismatched family members or matched
unrelated donors and 69–93% for HLA-identical sibling
donor HSCTs [39, 143, 144]. While FA patients are waiting
forasuitableHSCdonor,supportivecarecanbeprovidedvia
red blood cell and platelet transfusions; oral administration
of androgens such as oxymetholone, methyltestosterone, the
androgen analogue danazol; or the direct injection of growth10 Anemia
factors such as granulocyte-colony forming factor (G-CSF)
[145, 146]. However, androgen application can also lead to
adverse sideeﬀects like masculinization of female patients,
acne, hyperactivity and diverse problems associated with
the liver such as deranged liver enzymes, hepatic adenomas
and the potential risk of hepatic adenocarcinoma [147].
While hematopoietic growth factorssuch as G-CSF and GM-
CSF are capable of enhancing peripheral blood neutrophil
counts, and, in some cases platelets [148, 149], they should
be avoided in patients with clonal cytogenetic abnormalities
because of the risk of inducing leukemia. In any case, they
are only eﬀective for the short-term treatment and HSCT is
ultimately the deﬁnite therapy.
11. Gene Therapy of FA HSCs
Since the lack of availability of HLA-matched disease-free
donor HSCs is a major limitation in HSCT, one attractive
novel therapeutic modality is the genetic correction of
autologous patient HSCs via the reintroduction of the
d e f e c t i v eF Ac D N Au s i n gad e l i v e r ys y s t e ms u c ha sa
retroviral vector. Recent major advances have been made in
the ﬁeld of gene therapy, which has allowed the correction
of a range of diﬀerent inherited genetic disorders with a
hematologic basis via the retroviral-mediated delivery of
correcting cDNAs into patient HSCs [150, 151]. Since the
input cells are patient derived, there should be no issues with
immunologic rejection of the graft unless the vector system
or transgene payload is immunogenic. The phenomenon of
reverse mosaicism, that we have previously discussed, would
appear to indicate that FA would be an ideal candidate
disease for treatment via gene therapy, since correction
of an individual HSC can result in sustained reversal of
BMF [43]. Indeed, this ﬁnding has been recapitulated in
murine models of FA [99]. Unfortunately, FA also presents
some unique problems, which means that it may be an
incredibly diﬃcult disease to treat with gene therapy using
existing technologies. These include the extremely low yield
of CD34+ cells that can be collected for gene modiﬁcation
relative to those routinely achieved in non-FA patients; the
extreme sensitivity of FA cells to ex vivo culture [37, 92].
To date, the clinical gene therapy trials for FA have all
failed to achieve robust engraftment of corrected patient
HSCs, although advances have been made in the ability of
clinicianstotransduceFACD34+cellswithretroviralvectors
[37, 152, 153]. Fortunately, some of the model systems that
have been developed for FA have been able to assist in the
formulation of new strategies that may help overcome the
barriers to eﬀective gene therapy of FA.
The clinical gene therapy trial performed by Kelly and
colleagueshighlightedthelowcollectionyieldofCD34+cells
that are typically obtained from FA patients [37]. Initially,
HSC collection was attempted by apheresis of peripheral
bloodfollowingmobilizationwithG-CSF.Unfortunately,the
cohort of FA patients appeared to be refractory to the HSC-
mobilizing eﬀects of G-CSF. However, the ability of murine
models of FA to recapitulate this mobilization defect allowed
theevaluationoftwoalternatemobilization protocols.While
Milsom et al. were able to show that coadministration
of G-CSF with the Rac GTPase small molecule inhibitor
NSC23766 is able to rescue the mobilization defect of
Fanca−/− HSCs, Pulliam and colleagues were able to demon-
strate that the addition of the SDF1-α/CXCR4 antagonist
AMD3100 to a G-CSF mobilization regimen was able to
achieve similar results in both Fanca−/− and Fancc−/− mice
[154, 155].
An alternate route to overcome the barrier of limited
patient HSCs being available for genetic manipulation is to
enhance the ability of the gene-corrected cells to reconstitute
the patient. Murine models have been used to demonstrate
that the homing of transplanted HSCs to their niche in
the BM following intravenous injection into the recipient
is not 100% eﬃcient [156]. The postulation that direct
injection of HSCs into the intramedullary cavity might
enhance engraftment rates was ﬁrst demonstrated as a proof
of concept using the murine xenotransplantation assay and
may be of interest for the treatment of FA patients [157].
In order to reduce the loss of FA HSCs during in vitro
culture, it would be beneﬁcial to develop a transduction
protocol that minimized the ex vivo manipulation period.
To these ends, lentiviral and foamy retroviral vectors hold
the distinct advantage over gammaretroviral vectors in that
they are able to eﬃciently transduce nondividing HSCs and
therefore do not require ex vivo manipulation protocols that
involve a lengthy prestimulation step in order to drive the
largely noncycling HSC population to proliferate. Again,
using murine models of FA, two groups have independently
shown that the use of either lentiviral or foamy viruses to
deliver a correcting FA cDNA using a drastically shortened
transduction protocol, signiﬁcantly improves the engraft-
ment capacity of gene corrected cells [158, 159].
Onefurtherpossibilitytocompletelyovercometheprob-
lems associated with ex vivo transduction of FA HSCs is to
performthestemcellgenetransferinsitu.Theeﬃcacyofthis
novel approach was demonstrated by intrafemoral injection
of a lentiviral vector expressing GFP into adult immune-
competent mice. FACS analysis four months after injection
showed signiﬁcant transduction eﬃciency with up to 12% of
the cells, observed in myeloid and lymphoid subpopulations,
being positive for GFP. After secondary transplant, 8.1–
15% GFP-positive CFU were detectable and integration site
analysis conﬁrmed multiple transduced clones contributing
to hematopoiesis in these animals [160]. Importantly, Habi
and colleagues were able to extend these ﬁndings to the FA
model and show that intrafemoral injection of a lentivirus
encodingtheFANCC generesultedincorrectionofFancc
−/−
HSCs in vivo [161]. Altogether, this data indicates that in
situ transduction of adult stem cells using lentiviral vectors
is a promising improvement to ex vivo gene therapy. Indeed,
Frecha et al. have recently improved on this approach,
using normal donor and FA stem and progenitor cells to
demonstrate that specially modiﬁed lentiviral vectors can
selectively target human CD34+ cells in vitro and in vivo.
Using a novel vector system, which expresses an envelope
pseudotyped with a fusion of SCF and a mutant cat endoge-
nous retroviral glycoprotein, they were able to selectively
transduce target human CD34+ cells from nontarget cells in
unfractionated total cord blood and BM from FA patients.Anemia 11
In addition, the glycoprotein prevents degradation by the
human complement system and therefore makes the vector
suitable for in vivo use [162]. Ultimately, this vector system
may provide improved alternatives for gene therapy of FA
in vivo, as it allowed the selective transduction of human
CD34+ cells in vivo using the murine xenotransplantation
model.
One potential adverse side eﬀect of the use of integrating
vector systems to deliver correcting genes into HSCs is
the phenomenon of insertional mutagenesis. Insertional
mutagenesis arises as a result of the integrated vector
causing a change in expression of cellular genes that are
proximal to the integration site (reviewed by Muller et
al.) [163]. As documented in several clinical gene therapy
trials using retroviral vectors, this can sometimes result in
deregulatedexpression of protooncogenes, whichcanin turn
lead to malignant transformation [163]. In the setting of
FA, insertional mutagenesis might be particularly important
as promalignant mutations caused by the vector integration
may synergize with mutations that spontaneously arise as a
result of the genetic instability that is inherent to FA cells.
However, recent advances in the development of new vector
systems that may have less mutagenic potential could prove
a way to overcome this problem. These systems include
self-inactivating retroviral vectors with weaker promoter
enhancer elements [163]; recombinant transposons such as
the sleeping beauty retrotransposon [164]; vectors which
facilitate the codelivery of zinc ﬁnger nucleases in order to
facilitate the directed repair of the endogenous FA allele via
HR [165, 166]. The latter approach may prove particularly
challenging in the setting of FA, where the cells are deﬁcient
for some aspects of HR-mediated DNA repair.
12.AlternativeNovel Therapeutic Modalities
Targeting FA HSCs
Inadditiontogenetherapy,dataobtainedfromexperimental
models of FA have been used to devise other alterna-
tive novel therapeutic modalities for FA (summarized in
Figure 2). Metabolism is predicted to generate reactive by-
products, such as ROS and aldehydes, which are believed
to be one potential physiological source of DNA damage
that precipitates the FA phenotype. While healthy cells
protect against these threats through the combined action
of enzymatic detoxiﬁcation and DNA repair, FA cells clearly
show a defect in this respect.
As previously discussed, there is strong evidence that
FA cells are intolerant of oxidative stress as oxygen-induced
chromosomal aberrations were observed in cultured FA
cells [104] and hematopoietic cells from FA knockout
mice exhibit extreme oxidant sensitivity [107]. Therefore,
antioxidants promise to improve cell viability by conferring
resistance to apoptosis. FANCC-deﬁcient cells pretreated
with either selenomethionine or NAC are resistant to H2O2
treatment and demonstrate enhanced survival [107]. The
antioxidant drug resveratrol has been shown to partially
correct the hematopoietic defects of FANCD2-deﬁcient
mice such as reduced spleen colony-forming capacity and
abnormal cell cycle status. Colony forming unit-spleen
(CFU-S) assays with whole BM revealed a signiﬁcantly
improved frequency of primitive spleen colony forming cells
inresveratrol-treatedFancd2−/− mice.HSC/progenitorscells
derived from Fancd2−/− mice initially showed a signiﬁcantly
lower frequency of cells in G0 when compared to wild-type
counterparts; however, resveratrol treatment was capable of
increasing the total amount of cells in G0 by 27%. Most
importantly, a trial of treating FA patients with a two-
week infusion of recombinant human SOD was shown to
be eﬀective in decreasing ROS levels. Half of the patients
enrolled in this study (two out of four) were less sensitive
to DNA crosslinking agents and one had improved BM
progenitor numbers [167].
Recently, it was also found that the FA pathway genes
seem to be required in conferring resistance to reactive alde-
hydes, such as acetaldehyde and formaldehyde [117, 168].
They are thought to be a potential source of DNA damage as
they can directly modify DNA bases in vitro, which may then
lead to crosslinks with DNA or proteins. These ﬁndings raise
new therapeutic options for the treatment of FA patients.
For instance, it may be possible to therapeutically enhance
acetaldehyde/formaldehyde catabolic activity using small
molecule agonists of the ALDH2 and alcohol dehydrogenase
5, respectively, to provide an intrinsic mechanism for enzy-
matic detoxiﬁcation. Based on this data, it would also seem
prudenttorecommendthatFApatientsseverelyrestricttheir
intake of alcohol in order to prevent the accumulation of
acetylaldehydes.
A number of FA patients display enhanced serum
levels of TNF-α and IFN-γ, which were previously shown
to cause apoptosis of hematopoietic progenitor cells and
may therefore be one of the major driving factors in the
pathogenesis of BMF [27, 28, 30, 83, 122]. Pharmacologic
agents that inhibit the TNF-α-signaling pathway, such as
etanercept and inﬂiximab, have been suggested as a possible
therapeutic intervention directed against the pathogenesis of
proinﬂammatory cytokines and have already proven to be
eﬀective in clinical use for the treatment of inﬂammatory
diseases, such as rheumatoid arthritis and Crohn’s disease
[169]. They hold signiﬁcant promise for prolonging the
hematologic output in FA patients as preclinical models
have already demonstrated that inhibition of TNF-α using
etanercept was eﬀective in increasing the size and number of
CFU-E and BFU-E in BM cultures of FA patients [29]. In
addition, neutralization of TNF-α was shown to be eﬀective
in preventing excessive ROS production in FANCC-deﬁcient
mice and thereby signiﬁcantly reduced the DNA damage
p h e n o t y p ea sw e l la ss e n e s c e n c e[ 135].
13. Summary
FA is a fatal inherited disorder, which almost universally
results in severe defects of the hematopoietic system, likely
as a direct consequence of defective HSC biology. Advances
in our ability to model the HSC defect in FA patients have
not only enhanced our understanding of the underlying12 Anemia
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Figure 2: Potential novel therapeutic approaches for the prevention of FA HSC depletion. The potential physiologic mediators of FA HSC
depletion,includingreplicative stress,TNF-α,ROS,lipopolysaccharide (LPS),and reactivealdehydes, aredepicted asgreen arrows.Exposure
ofFAHSCstotheseagents/conditionswouldbepredictedtoresultinDNAdamageandultimatelylossofthecellviaapoptosisorsenescence.
Novel therapeutic modalities that directly target these HSC-depleting stimuli are shown in red. Controlling dietary consumption of certain
food types (e.g., alcohol) may reduce the production of high levels of reactive aldehyde species in FA patients. Intracellular ROS could be
decreased via treatment with antioxidants or ROS scavengers. Proinﬂammatory cytokine signaling could be targeted by interfering with
ligand-receptor binding (e.g., using etanercept or inﬂiximab to block interaction of TNF-α with its receptors) or by inhibiting downstream
signaling cascades, as demonstrated for HOXB4 overexpression in the context of TNF-α signaling. Finally, gene therapy approaches oﬀer the
possibility of restoring expression of a functional FA gene into patient HSCs.
etiology of this disease but have also highlighted novel
targets for therapeutic intervention. One challenge for the
immediate future is to determine whether the defects that
have so far been identiﬁed in FA HSCs can be extrapolated
to explain the abnormal biology of other tissues that are
commonly impacted upon by a defect in the FA signaling
pathway. This is of particular importance since there are very
limited treatment options for the serious nonhematologic
complications observed in FA patients such as the increased
predisposition towards solid tumors.
AlthoughFAisarelativelyraredisease,itispredictedthat
FA HSCs can, in some instances, act as an extremely sensitive
experimental model system to interrogate the biology of
normal HSCs. Therefore, understanding the behavior of
FA HSCs not only beneﬁts the community of FA patients,
but may potentially impact upon our knowledge of more
common disorders such as leukemias, myeloproliferative
disorders, and other BMF syndromes such as acquired
aplastic anemia.
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